Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00624468 · ClinicalTrials.gov registry record · Phase 2
Atacicept in Subjects With Optic Neuritis
A Phase 2 study, sponsored by EMD Serono.
- Terminated
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT00624468 is a Phase 2 study that was terminated before completion, run by EMD Serono. The registered enrollment target is 34 participants.
The verdict
NCT00624468, a Phase 2 study, was terminated before completion, sponsored by EMD Serono.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study was intended to evaluate the efficacy, safety and tolerability of atacicept compared to placebo and to explore the neuroprotective effect of atacicept as assessed by OCT in subjects with ON as CIS. The study was randomized. Study medication was administered via subcutaneous (under the skin) injections.
Interventions
- DRUG Atacicept
- DRUG Placebo matched to atacicept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2008-06 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00624468
The ClinicalTrials.gov registry entry for NCT00624468 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atacicept is the first listed.
NCT00624468 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00624468 about?
NCT00624468 is a clinical study titled "Atacicept in Subjects With Optic Neuritis". This study was intended to evaluate the efficacy, safety and tolerability of atacicept compared to placebo and to explore the neuroprotective effect of atacicept as assessed by OCT in subjects with ON as CIS. The study was randomized. Study medication was administered via subcutaneous (under the ski...
What is the current status of trial NCT00624468?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2008-06. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00624468?
The interventions under investigation include: Atacicept (DRUG), Placebo matched to atacicept (DRUG).
Who is sponsoring clinical trial NCT00624468?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.